Resumen de: EP4187246A1

An object of the present invention is to provide a method of assisting diagnosis of inflammatory bowel disease, which can specifically determine inflammatory bowel disease.The present invention relates to "a method of assisting diagnosis of inflammatory bowel disease, the method including subjecting a subject-derived specimen to a reduction treatment and subsequently measuring a human prohaptoglobin amount in the specimen by using an antibody 1 which is an antibody that specifically binds to an amino acid sequence set forth in SEQ ID NO: 1, and determining that a subject has inflammatory bowel disease by using the human prohaptoglobin amount as an indicator, and relates to an examination kit for assisting diagnosis of inflammatory bowel disease, including the antibody 1 a reducing agent".

Resumen de: WO2017189338A2

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤ 0.07 as determined by their raw p-value or an average discriminatory p-value of ≤ 0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

Resumen de: WO2017189338A2

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤ 0.07 as determined by their raw p-value or an average discriminatory p-value of ≤ 0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

Resumen de: WO2021209540A1

The present invention relates to a sandwich immunoassay and kits for detecting in a biological sample cross-linked CTX-III, and its use in evaluating the efficacy of drugs targeting lysyl oxidases (LOXs). Cross-linked CTX-III can be used as a biomarker in diseases associated with fibrosis, including liver fibrosis, chronic intestinal disease, eosinophilic esophagitis and cancer.

Resumen de: US2023158082A1

The present invention relates to vesicles derived from bacteria of the genus Coprococcus and a use thereof, and the inventors experimentally confirmed that the vesicles were significantly reduced in clinical samples obtained from patients with breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy and atrial fibrillation, compared with a normal individual, and that when vesicles isolated from the strain were administered, the secretion of inflammatory mediators caused by pathogenic vesicles, such as E. coli-derived vesicles, was significantly inhibited. Therefore, it is expected that the vesicles derived from bacteria of the genus Coprococcus according to the present invention can be effectively used for a method of diagnosing breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy or atrial fibrillation, and for developing a composition for preventing, treating or alleviating gastritis, gastric cancer, colitis, colon cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation or an inflammatory disease.

Resumen de: US2023159505A1

The present invention discloses a number of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.

Resumen de: AU2021364203A1

Compositions containing live cultures of 11 separately isolated bacterial strains (the bacterial consortium containing all 11 strains designated GUT-108) are provided for treating conditions of systemic inflammation including, to name a few, Inflammatory Bowel Diseases, type-2 diabetes, metabolic syndrome and obesity, and aging-related conditions of chronic inflammation. In a mouse model of chronic immune-mediated colitis, therapeutic application of GUT-108 reversed the established inflammation in the cecum. In addition, the treatment with GUT-108 unexpectedly resulted in restoration of a healthy gut microbiome in the mice containing an abundance of beneficial

Resumen de: EP4183804A1

The present invention relates to the treatment of inflammatory bowel disease (IBD) with anti-IL36R antibodies.

Resumen de: EP4183403A1

We provide a method for preparing an oral capsule containing Gram-positive bacteria-enriched fecal-origin bacteria population. Bacteria were separated from the fecal matter by centrifugation and Gram-positive bacteria were further enriched by fluorescence activated cell sorting (FACS) method, using Gram-positive bacteria-specific (Wheat germ agglutinin, WGA) and/or DNA-specific (DAPI) markers. Capsules containing Gram-positive bacteria-enriched bacterial population may benefit for a higher effectiveness of fecal microbiota transplantation in inflammatory bowel disease patients or in patients with other conditions where a higher number of Gram-positive bacteria is required. These conditions, that are associated with low-grade gut inflammation mediated by certain Gram-positive bacteria, include obesity with metabolic syndrome, diabetes mellitus, and even some variants of irritable bowel syndrome. We also provide results of the bacterial composition analysis that was performed on the constituents of the capsule, that revealed a significant increase of Gram-positive bacteria in the sorted bacterial samples with the highest number of Gram-positive bacteria in samples sorted based on the WGA marker.

Resumen de: AU2023202551A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).

Resumen de: US2023152314A1

The present invention relates to the field of short bowel syndrome. More specifically, the present invention provides methods and compositions useful for assaying for intestinal adaptation. In a specific embodiment, a method for treating a patient having SBS who is undergoing parenteral nutrition comprises the steps of (a) measuring lipocalin-2 (LCN2) in a sample obtained from the patient; and (b) reducing or eliminating parenteral nutrition if the measured level of LCN2 is below a control level or treating the patient with IL-22, a LCN2 inhibitor and/or an AHR agonist if the measured level of LCN2 is above the control level.

Resumen de: EP4180059A1

Disclosed is use of phosphatidylserine as a target for treating inflammatory bowel disease. Phosphatidylserine can be used as a marker of inflammatory bowel disease and used for drug screening. Annexin A5 can be traced by phosphatidylserine in the extracellular membrane and indicate the location of lesions and extent of inflammatory bowel disease, and can be used to treat inflammatory bowel disease. Better anti-inflammatory effects can be generated by mutating Annexin A5.

Resumen de: WO2023078435A1

The present invention relates to the technical field of biomedicine. Disclosed is an application of folic acid in prevention, diagnosis, and treatment of hereditary, infectious, or allergic diseases. It is found in the present invention that folic acid promotes expression of Nox2 by improving inflammation, regulating metabolism of an iron ion, correcting disturbance of intestinal flora, alleviating liver/intestinal tissue damage, and inhibiting expression of an inflammatory factor, to achieve prevention and treatment of hereditary, infectious, or allergic diseases. Meanwhile, the present invention provides an application of one or more of folic acid, S100a8, S100a9, Nox2, and IFN-γ as a diagnostic or auxiliary diagnostic marker for biliary atresia. Meanwhile, provided is folic acid or a derivative thereof which is prepared as food, nutritional preparation, or medicine, is used in children or adults, and achieves the purpose of prevention and treatment of related diseases such as biliary atresia, cholangitis, jaundice, infectious diseases, and bowel diseases and diseases caused by abnormal folic acid metabolism.

Resumen de: WO2021016083A1

Described herein are compositions and methods for the delivery of microbial therapeutics useful for the treatment of disorders related to intestinal dysbiosis. Described herein are compositions and methods for protecting the Gl microbiome of a subject. In various embodiments, provided herein is a pharmaceutical composition comprising an isolated or purified bacterial isolate and/or a cocktail of isolated or purified bacterial isolates (e.g. from a human, e.g. from stool of a healthy human).

Resumen de: WO2023076740A1

Inflammatory bowel disease (IBD) in humans and dogs and other companion animals is characterized by infiltration of lymphocytes and macrophages into the mucosa and submucosa and clinical signs of gastrointestinal (Gl) dysfunction (diarrhea, malabsorption, weight loss). Alteration of the gut environment and development of dysbiosis may allow the overgrowth of pathogenic bacteria and induction of intestinal injury and inflammation in IBD. What is needed are novel methods that allow for rapid diagnosis of IBD (and follow-up monitoring) and treatment of the disease. The present disclosure relates to methods for diagnosing and treating inflammatory bowel disease (IBD) or gastrointestinal lymphoma.

Resumen de: US2023130204A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).

Resumen de: US2023127277A1

Provided herein is a method of treating an individual afflicted with an inflammatory bowel disease utilizing Candida abundance as a biomarker of responsiveness. The method comprises determining levels of Candida in a sample from the gastrointestinal tract of an individual, and if the level of Candida is higher than a reference level, identifying the individual as suitable for microbiota transplantation therapy (MTT), and optionally, administering to such an individual the MTT, and in individuals having gastrointestinal tract Candida levels lower than a reference level, increasing the Candida levels prior to prior to administration of MTT.

Resumen de: WO2023067186A1

The present invention relates to a method of determining whether a patient in remission from ulcerative colitis (UC) is in stable remission, said method comprising quantifying the level of gene expression of IFNG and IL33 in a gastrointestinal (Gl) mucosal sample from said patient and comparing said expression levels; in particular wherein a high level of expression of IL33 relative to IFNG is prognostic of stable remission and a level of expression of IL33 relative to IFNG which is not high, is prognostic of relapse.

Resumen de: US2023122171A1

The disclosure relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23, but do not inhibit IL-12. The disclosure also relates to methods of selecting a subject amenable to IL-23 inhibition therapy to treat Crohn's disease as well as methods of identifying a patient sub-population amenable to such treatment.

Resumen de: US2023116530A1

The invention relates to a method for detecting and measuring the presence of mono-nucleosomes and oligo-nucleosomes and nucleosomes that contain particular histone variants and the use of such measurements for the detection and diagnosis of disease. The invention also relates to a method of identifying histone variant biomarkers for the detection and diagnosis of disease and to biomarkers identified by said method.

Resumen de: WO2021247548A1

Described herein are methods and systems for identifying subpopulations of patients having Crohn's disease, including populations at risk of developing stricturing or other severe disease, and populations susceptible to success or failure with surgical intervention. Further provided are therapies useful for treating subpopulations of patients having Crohn's disease.

Resumen de: WO2023055955A1

Provided are systems and methods for treating an immune-mediated inflammatory disease (e.g., inflammatory bowel disease) in a subject or selecting the subject for treatment, based on an estimated time to remission following induction of an anti-TNF therapy calculated by a patient-centric precision model.

Resumen de: WO2023056417A1

The present disclosure is generally relates to methods of treating ulcerative colitis. The methods are particularly suitable for treating bowel urgency a specific sub-group of patients with ulcerative colitis and having bowel urgency.

Resumen de: WO2022031954A1

Some embodiments described herein relate to a method of screening candidate therapeutics for gastrointestinal diseases, including inflammatory bowel diseases, ulcerative colitis, and Crohn's Disease, using an ex vivo biopsy high throughput platform. Some embodiments relate to a high-throughput method of screening an ex vivo biopsy for chromatin modifications associated with an gastrointestinal disease. Some embodiments relate to a multi-omic method of screening candidate therapeutics for treatment of gastrointestinal diseases, including inflammatory bowel diseases, ulcerative colitis, and Crohn's Disease.

Resumen de: WO2023049838A1

The invention relates to diagnostic and therapeutic methods for inflammatory bowel disease. Disclosed is a method of differentiating between ulcerative colitis (UC) and Crohn's disease (CD) in a subject having an inflammatory bowel disease (IBD) comprising determining a level of one or more of SEQ ID NOs:1-590 in a sample from the subject.